Safety, Tolerability and Pharmacokinetics of Oral CPL304110, in Adult Subjects With Advanced Solid Malignancies

Gastric Cancer Clinical Trial

Official title:

A Phase I, Open-label, Multicentre, Dose Escalation Study to Assess Safety, Tolerability and Pharmacokinetics of Oral CPL304110, in Adult Subjects With Advanced Solid Malignancies

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04149691
• Other study ID #: 01FGFR2018
• Status: Recruiting
• Phase: Phase 1
• Start date: July 19, 2019
• Est. completion date: June 2024

Study information

• Verified date: February 2024
• Source: Celon Pharma SA
• Contact: CROS CRO
• Phone: +48 791 690 990
• Email: clinicaltrials[@]cros-cro.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of the study is to determine to evaluate safety and tolerability of CPL304110 when administered once daily to adults with advanced solid malignancies.

Description:

01FGFR2018 is an Open-label, Multicentre, Dose Escalation Study to Assess Safety, Tolerability and Pharmacokinetics of Oral CPL304110, in Adult Subjects with Advanced Solid Malignancies. The study consists of 3 parts: initial dose escalation (Part 1 - without FGFR, fibroblast growth factor receptor, molecular aberrations), dose escalation (Part 2 - with FGFR molecular aberrations) and dose extension (Part 3 - with FGFR molecular aberrations).

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 42
• Est. completion date: June 2024
• Est. primary completion date: June 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 25 Years and older

Eligibility

Inclusion Criteria:

• Patient or legal guardian, if permitted by local regulatory authorities, provides informed consent to participate in the study must be performed before any procedure's protocol related
• age of =25 years old
• Performance Score =70 in accordance with the Karnofsky Performance Score (KPS),
• life expectancy period of at least 3 months on the screening day,
• Have measurable disease according to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1)
• subject (or his/her partner) of childbearing potential willingness to use acceptable forms of contraception
• adequate blood, liver, renal and urine parameters
• phosphate levels within normal range
• HIV, HCV (hepatitis C virus) and HBV negative (hepatitis B virus),
• adequate cardiac function Inclusion Criteria Specific for parts: Part 1
• Patients with histologically confirmed advanced gastric cancer, bladder cancer, squamous lung cancer or non-small cell lung cancer with squamous immunophenotype, cholangiocarcinoma, sarcoma or endometrial cancer, be refractory to prior therapies and without effective further treatment options. Part 2 and 3
• Patients with histologically confirmed advanced gastric cancer, bladder cancer, squamous lung cancer or non-small cell lung cancer with squamous immunophenotype, be refractory to prior therapies and without effective further treatment options.
• Subject's archival formalin-fixed paraffin-embedded (FFPE) tumour sample available for molecular alteration diagnostics, and/or a possibility to collect a new biopsy.
• Present molecular alteration within FGFR 1, 2 or 3

Exclusion Criteria:

• Any other current malignancy or malignancy diagnosed within the past five (5) years.
• Active brain metastases or leptomeningeal metastases.
• concurrent anticancer treatment within 28 days before the start of trial treatment; major surgery within 28 days before the start of trial treatment); use of blood transfusion within 7 days before the start of trial treatment,
• prior therapy with an agent directed to another FGFR inhibitor,
• pregnancy and/or breastfeeding,
• phosphate levels above the upper limit of normal,
• ectopic calcification/mineralization,
• endocrine alteration related to calcium/phosphate homeostasis e.g. parathyroid disorders, history of parathyroidectomy,
• concomitant therapies increasing calcium/phosphate serum levels,
• inability to take oral medicines,
• corneal disorder and/or keratopathy,
• persisting toxicity related to prior therapy Grade > 1 CTCAE v5.0, except polyneuropathy and alopecia,
• clinically significant (i.e., active) cardiovascular disease. History of abdominal fistula, bowel obstruction (Grade IV), gastrointestinal perforation, intra-abdominal abscess within 6 months of enrollment. Other significant diseases, which, in the opinion of the investigator, might impair the subject's tolerance of trial treatment.
• Receipt of any organ transplantation including allogeneic stem-cell transplantation. Exclusion Criteria Specific for parts: Part 2 and 3
• No FFPE tumour sample available to conduct FGFR alteration eligibility tests and no biopsy option.

Related Conditions & MeSH terms

• Bladder Cancer
• Carcinoma, Non-Small-Cell Lung
• Cholangiocarcinoma
• Endometrial Cancer
• Endometrial Neoplasms
• Gastric Cancer
• Other Solid Tumours
• Sarcoma
• Squamous Non-small Cell Lung Cancer
• Stomach Neoplasms
• Urinary Bladder Neoplasms

Intervention

Drug:
• CPL304110
CPL304110 is to be administered orally as hard gelatine capsules once daily in 28-day cycles.

Locations

Country	Name	City	State
Poland	Uniwersyteckie Centrum Kliniczne w Gdansku	Gdansk
Poland	BioResearch Group sp. z o.o.	Nadarzyn
Poland	SP ZOZ MSWiA z Warminsko-Mazurskim Centrum Onkologii w Olsztynie	Olsztyn
Poland	Klinika Onkologii, Europejskie Centrum Zdrowia	Otwock
Poland	Centrum Onkologii - Instytut im. Marii Sklodowskiej-Curie	Warsaw
Poland	Instytut Gruzlicy i Chorób Pluc	Warsaw
Poland	Wojskowy Instytut Medyczny	Warsaw

Sponsors (2)

Lead Sponsor	Collaborator
Celon Pharma SA	National Center for Research and Development, Poland

Country where clinical trial is conducted

Poland, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Maximum tolerated dose (MTD)	Maximum tolerated dose (MTD) of CPL304110 when administered orally once daily to adults with advanced solid malignancies. The MTD is the highest dose associated with the occurrence of dose-limiting toxicities (DLTs) in <33% of patients.	First cycle of 28 days
Primary	Safety profile	Overall safety profile of CPL304110, as assessed by the type, frequency, severity, timing, and relationship to study drug of any adverse events (AEs), serious adverse events (SAEs), and changes in vital signs, ECGs, and safety laboratory test.	First cycle of 28 days
Secondary	Recommended Phase 2 Dose (RP2D) determined on the base of the MTD.	The RP2D will be determined after review and discussion of the pharmacokinetics (PK) profile, type and severity of drug related toxicity and clinical suitability for long-term administration.	Approximately up to 12 months
Secondary	ORR, objective rate response	ORR, objective rate response defined as the rate of confirmed complete response (CR) or partial response (PR) by RECIST 1.1.	Approximately up to 12 months
Secondary	Maximum plasma concentration (Cmax)	Cmax defines the maximum concentration of the product in plasma during observation period.	up to 24 hours after CPL304110 administration
Secondary	Time to maximum plasma concentration (tmax)	tmax defines Time to reach maximum plasma concentration	up to 24 hours after CPL304110 administration
Secondary	Area under the plasma concentration versus time curve (AUC) from 0 up to the time of last quantifiable concentration (AUC0-t)	AUC(0-t) defines the area under the curve of plasma concentration vs time, from time point zero up to the time of last quantifiable concentration	up to the time of last quantifiable concentration after CPL304110 administration
Secondary	Area under the plasma concentration versus time curve AUC from 0 to infinity (AUC0-inf)	AUC0-inf defines the area under the curve of plasma concentration vs time, from time point zero extrapolated to infinity	up to 24 hours after CPL304110 administration
Secondary	Terminal half-life (t½)	Plasma elimination half-life	up to 24 hours after CPL304110 administration
Secondary	Kel: Terminal elimination rate constant	Terminal elimination rate constant	up to 24 hours after CPL304110 administration